NuCana plc
NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer medicines based on its ProTide phosphoramidate chemistry platform. The company is incorporated in England and Wales, with principal operations in Edinburgh and a U.S. subsidiary structure supporting its development and U.S. market access.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2022–2025
Liiketoiminta
Osuus liikevaihdostaDrug candidates built on NuCana's ProTide chemistry for cancer treatment.
Chemistry platform used to design new nucleoside-based medicines.
Asiakkaat
NuCana does not sell to consumers; its end users are cancer patients, while its direct commercial counterparties are research partners, clinical sites, and potential licensing or development partners. The company's value proposition is to advance differentiated oncology drug candidates through clinical development so that future commercialization can be supported by a larger pharmaceutical partner or its own infrastructure.
Ultimate end users of NuCana's oncology medicines if approved.
Hospitals and research centers running studies of NuCana's candidates.
Potential licensing or development partners for candidates and platform assets.
Providers and treatment centers that would prescribe approved oncology therapies.
Strategia
NuCana's strategy is centered on advancing its ProTide platform through clinical development and generating evidence that its compounds can improve cancer treatment. The business depends on selecting attractive oncology targets, moving candidates through trials, and building optionality for partnering, licensing, or eventual commercialization.
Clinical data are the core source of value for a development-stage biopharma company.
Platform validation can support multiple programs and improve partnering appeal.
Clinical biopharma companies need access to external capital to fund multi-year trials.
Maantiede
NuCana is headquartered and principally operated from the United Kingdom, with corporate and research activity centered in Edinburgh and London. It is also listed in the United States through Nasdaq ADSs and has a U.S. subsidiary, which matters for capital markets access and development activities, but no country-by-country revenue disclosure is provided because the company is pre-revenue.
Riskit
NuCana faces the typical risks of a clinical-stage biopharmaceutical company: trial failure, uncertain regulatory outcomes, and long development timelines before any product revenue can emerge. Its value is concentrated in a small number of oncology programs and a single platform technology, so clinical setbacks, funding needs, or partnering delays can have outsized impact.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
The company depends on proving that its oncology candidates are effective and safe in trials.
Kohdistuu: Product pipeline
- Financing riskVaikutus: KorkeaTodennäköisyys: Korkea
Clinical-stage biopharma companies often require ongoing external capital before product sales.
Kohdistuu: Corporate liquidity and development spend
- Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even positive clinical data may not translate into market authorization.
Kohdistuu: Lead candidates
- Pipeline concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
A narrow asset base means setbacks in one program can materially affect enterprise value.
Kohdistuu: ProTide platform and oncology pipeline
- Foreign exchange exposureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The group operates with UK reporting currency and international cash balances/operations.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätClinical program costs are typically expensed as incurred, so trial timing changes reported loss.
Vaikutus: Affects operating loss and comparability across quarters
The group reports in pounds sterling but has international operations and cash balances.
Vaikutus: Creates other comprehensive income volatility
Employee and director equity awards can be a meaningful non-cash expense for biopharma firms.
Vaikutus: Affects operating expense and loss per share
Development-stage companies must assess whether available cash supports planned programs.
Vaikutus: Influences disclosure and investor perception of financing risk
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
Processa Pharmaceuticals, Inc.
PCSA · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Lisata Therapeutics, Inc
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
Päivitetty: 28.9.2026